ClinicalTrials.gg
RecruitingNCT06843902INFORM_2Updated Sep 8, 2026

Improving Coronary Vascular Health in Women

A Phase 2 interventional study of Health Education and Subspecialty clinic referral in HIV-1-infection, Coronary Microvascular Dysfunction and Metabolic Disease, sponsored by Massachusetts General Hospital. Recruiting at 1 site in United States. Open to female participants aged 45 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-08.

Sponsored by Massachusetts General Hospital · Phase 2, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
45 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Metabolic Diseases by Massachusetts General Hospital — 3 open to participants now, 3 under way, none of them phase 3. Metabolic Diseases · Massachusetts General Hospital.

Started
2025
the only one that year
Phase 2
Only one
of the 10
Registered
9th of 10
by date

Among the 10 studies in Metabolic Diseases by Massachusetts General Hospital, this one is the only one that started in 2025, is the only one in phase 2, and was the 9th registered.

Metabolic Diseases

765 studies on the registry are indexed under Metabolic Diseases; 194 are open to participants now.

Browse Metabolic Diseases studies →

Open to participants now

3 of the 10 studies in Metabolic Diseases by Massachusetts General Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 135 Metabolic Diseases studies recruiting now, 47 (35%) set no upper age limit and 64 (47%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 45 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Metabolic Diseases by Massachusetts General Hospital, or all of them as a file.
02

Study summary

Women with HIV have an increased risk of having a myocardial infarction (heart attack) as compared to women without HIV. One of the mechanisms underlying the increased risk of myocardial infarction among women with HIV may involve reduced ability to increase blood flow through large and small coronary arteries at times when increased flow of oxygen-carrying blood is needed. We are conducting a study randomizing women with HIV and either diabetes, chronic kidney disease, or both to health education alone or to health education plus referral to see either an Endocrinologist or a Nephrologist in a subspecialty clinic for consideration of treatment with medication in a class known as sodium glucose transporter 2 (SGLT2) inhibitors. SGLT2 inhibitors are clinically approved for use in patients with diabetes or chronic kidney disease but have been shown to be underutilized in people with HIV. One of our key analytic aims will be to test if SGLT2 inhibitor therapy results in improved blood flow through the large and small coronary arteries among women with HIV and either diabetes, chronic kidney disease, or both but who have no history of myocardial infarction. A second aim will be to test if subspecialty clinic referral (with or without SGLT2 inhibitor therapy prescription) results in improved blood flow through the large and small coronary arteries among the same group.

Read the detailed description

Women with HIV have an increased risk of having a myocardial infarction (heart attack) as compared to women without HIV. One of the mechanisms underlying the increased risk of myocardial infarction among women with HIV may involve reduced ability to increase blood flow through large and small coronary arteries at times when increased flow of oxygen-carrying blood is needed. We are conducting a study randomizing women with HIV and either diabetes, chronic kidney disease, or both to health education alone or to health education plus referral to see either an Endocrinologist or a Nephrologist in a subspecialty clinic for consideration of treatment with medication in a class known as sodium glucose transporter 2 (SGLT2) inhibitors. SGLT2 inhibitors are clinically approved for use in patients with diabetes or chronic kidney disease but have been shown to be underutilized in people with HIV. Prior to randomization, to confirm eligibility, participants will have undergone history, physical, lab tests, and cardiac positron emission tomography/computed tomography (PET/CT) scanning to confirm that there is a measure of impairment in stimulated blood flow through the large and small arteries of the heart. Randomized participants in both groups will be followed for 6 months and then will undergo repeat history, physical, laboratory testing, and repeat cardiac PET/CT scanning. One of our key analytic aims will be to test if SGLT2 inhibitor therapy results in improved blood flow through the large and small coronary arteries among women with HIV and either diabetes, chronic kidney disease, or both but who have no history of myocardial infarction. A second aim will be to test if subspecialty clinic referral (with or without SGLT2 inhibitor therapy prescription) results in improved blood flow through the large and small coronary arteries among the same group. We will also investigate effects of SGLT inhibitor therapy (and, separately, of subspecialty clinic referral) on fat tissue around the heart, as well as on blood and urine-based markers of metabolic disease and inflammation.

03

Conditions studied

  • HIV-1-infection
  • Coronary Microvascular Dysfunction
  • Metabolic Disease

Keywords

  • HIV
  • women
  • diabetes
  • chronic kidney disease
  • SGLT2 inhibitor therapy
  • coronary flow reserve
  • cardiovascular disease prevention
04

Who can participate

Ages eligible
45 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • female sex-at-birth
  • self-report of on stable antiretroviral therapy ≥180 days
  • age 45 -75 years
  • at least 1 of the following 3 conditions: i) type 2 diabetes mellitus ii) estimated 30-60 ml/min/1.73 m2 iii) urine albumin to creatinine ratio >30 mg/g
  • coronary flow reserve \<2.5 or stress myocardial blood flow \<2.5 on screening cardiac positron emission tomography/computed tomography

Exclusion criteria

Exclusion Criteria:

  • current SGLT2 inhibitor use
  • known allergy to SGLT2 inhibitor use
  • type 1 diabetes or ketoacidosis prone diabetes (diabetes with a history of ketoacidosis)
  • self-reported history of polycystic kidney disease
  • self-reported history of myocardial infarction, stroke, or coronary revascularization
  • stable or unstable angina
  • self-reported history of heart failure
  • ≥8.5% at screen
  • uncontrolled hypertension at screen, defined as systolic blood pressure ≥180 mm Hg and/or diastolic blood pressure ≥110 mm Hg
  • estimated \<30 ml/min/1.73 m2
  • currently receiving hemodialysis or peritoneal dialysis
  • CD4 \<400 cell/mm3
  • current treatment with systemic (oral, IV, IM or intra-articular) or anti-inflammatory/immune suppressant therapies (excluding topical therapies, UV therapy, ASA-derivatives, or NSAIDs) for any indication, including kidney disease
  • pregnancy or breastfeeding
  • known allergy to 13N Ammonia/82Rubidium or to Regadenoson/Adenosine
  • concurrent enrollment in conflicting research study
  • self-reported history of recurrent urinary tract-infections (≥2 urinary tract infections within 6 months or ≥3 within a year) and/or recurrent vaginal yeast infections (≥2 vaginal yeast infections within 6 months or ≥3 within a year)
  • currently receiving 24-hour-a-day home oxygen therapy
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Health education plus subspecialty clinic referral for consideration of SGLT2 inhibitor therapy

    Participants randomized to this study arm will receive health education and will be referred to establish clinical care in either the MGH Lipid and Metabolism Clinic or the MGH Renal Clinic for consideration of SGLT2 inhibitor therapy. By study design (inclusion criteria), participants will have a clinical indication for SGLT2 inhibitor therapy (either diabetes or chronic kidney disease). SGLT2 inhibitor therapy (e.g. empagliflozin 10 mg by mouth daily or dapagliflozin 10 mg by mouth daily) may or may not be prescribed by the subspecialty clinician as part of routine clinical care, according to the clinician's clinical judgement. Participants will also receive health education.

    Other: Health Education

  • Other
    Health Education

    Participants randomized to this study arm will receive health education alone.

    Other: Health Education · Other: Subspecialty clinic referral

Interventions

  • OtherHealth Education

    Health Education

  • OtherSubspecialty clinic referral

    This intervention will entail referred to establish clinical care in either the MGH Lipid and Metabolism Clinic or the MGH Renal Clinic for consideration of SGLT2 inhibitor therapy. SGLT2 inhibitor therapy (e.g. empagliflozin 10 mg by mouth daily or dapagliflozin 10 mg by mouth daily) may or may not be prescribed by the subspecialty clinician as part of routine clinical care, according to the clinician's clinical judgement.

06

What researchers measure

Primary outcomes

  1. Coronary Flow Reserve

    Change in coronary flow reserve by cardiac positron emission tomography

    Time frame: 24 weeks

  2. Ectopic Adipose Tissue

    Change in ectopic adipose tissue reserve by cardiac computed tomography

    Time frame: 24 weeks

Secondary outcomes

  1. Kidney-related biomarkers

    Urine and serum biomarkers related to kidney health and disease

    Time frame: 24 weeks

  2. Metabolic biomarkers

    Urine and serum biomarkers relating to metabolism (including glucose and lipid metabolism)

    Time frame: 24 weeks

  3. Immune/inflammatory biomarkers

    Urine and serum biomarkers relating to inflammation and immune activation

    Time frame: 24 weeks

  4. HIV-specific parameters

    Serum variables relating to HIV disease (such as HIV-1 viral load, CD4 T cell count, CD8 T cell count)

    Time frame: 24 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Plans are for IPD to be shared to the NIH BioLINCC data repository.

Supporting information: Study protocol, Informed consent form

Time frame: Data will be made available 12 months after study completion and will remain available for a duration of time consonant with NIH policies.

Access criteria: Access criteria are as per the NIH BioLINCC data repository.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Mar 2029, 47 months after the start.

Of 27 phase 2 interventional studies under Metabolic Diseases, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 58. This study's planned 47 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2025
First posted
Feb 25, 2025
StartActual
Apr 17, 2025
Primary completionEst.
Mar 2029
CompletionEst.
Jun 2029
Last update
Sep 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06843902
Responsible party
Markella V. Zanni,M.D. (Associate Professor of Medicine, Harvard Medical School, Massachusetts General Hospital) — Principal investigator
First posted
Feb 25, 2025
Start date
Apr 17, 2025
Primary completion
Mar 2029 (estimated)
Completion
Jun 2029 (estimated)
Last update
Sep 8, 2026

Study contacts

Sarah Chu, NP
Contact
schu4@mgh.harvard.edu
617-724-6091
Markella V Zanni, MD
principal investigator · MGH/HMS

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion